Rein Earnings|Guidance|M&A|Buyback|Dividend|Leadership|Restructuring|Regulatory|Legal|Cyber|Offering|Bankruptcy|Other Monday, November 16, 2026 +0.30 Positive

Rein Therapeutics announces preliminary Phase 2 IPF data for LTI-03

Rein Therapeutics reported preliminary Phase 2 blinded data for LTI-03 in idiopathic pulmonary fibrosis, showing an improvement in FVC for 33% of patients. The company also provided a business update noting 75% study enrollment.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed